Amgen's $1.9bn looks buried
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
One of Adcetris’s twin sons strikes out
Pfizer cans PF-08046045, but keeps PF-08046044 for now.
Nuvation reroutes its glioma plan
The company will no longer initiate a head-to-head trial of safusidenib against Voranigo.
Venture capitalists buy into TROP2
Blackstone follows Abingworth, but why?
Gastrointestinal is next for pumitamig
Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
Caribou finds a match
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?
FDA red and green lights: October 2025
Syndax’s Revuforj beats Kura in NPM1-mutated AML.
Henlius goes on the anti-Pfizer offensive
But the extensively curated dataset covering its anti-PD-L1 ADC raises more questions.
Moderna takes on IO Biotech
The group is expanding its mRNA-4359 trial to include first-line melanoma.
The month ahead: November’s upcoming events
FDA decisions loom for Kura’s ziftomenib and Bayer’s sevabertinib.
